Metformin and risk of hematological cancers in patients with diabetes: a systematic review and meta-analysis
The effect of metformin use in patients with diabetes against the hematological cancers (HCs) has been contradictory. This meta-analysis, carried out on studies published in databases, aimed to investigate the association of metformin use and the odds of HCs. We systematically searched Scopus and Pu...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
King Faisal Specialist Hospital and Research Centre
2024-03-01
|
Series: | Annals of Saudi Medicine |
Online Access: | http://www.annsaudimed.net/doi/10.5144/0256-4947.2024.126 |
_version_ | 1797205284890869760 |
---|---|
author | Min Wang Giti Noghabaei Tahereh Raeisi Dandan Li Hamzeh Alizadeh Mohammad Alizadeh |
author_facet | Min Wang Giti Noghabaei Tahereh Raeisi Dandan Li Hamzeh Alizadeh Mohammad Alizadeh |
author_sort | Min Wang |
collection | DOAJ |
description | The effect of metformin use in patients with diabetes against the hematological cancers (HCs) has been contradictory. This meta-analysis, carried out on studies published in databases, aimed to investigate the association of metformin use and the odds of HCs. We systematically searched Scopus and PubMed databases to include related studies considering the relation of metformin use and the risk of HCs as outcome. Eleven studies, comprising a total of 2 318 217 participants, were included. The analysis revealed that metformin use in patients with diabetes was significantly associated with a decreased risk of HCs (OR=0.88; 95%CI: 0.79–0.98), with significant heterogeneity. In the subgroup analysis, this association was found to be significant only for multiple myeloma (OR=0.67; 95% CI: 0.55–0.81). A significant evidence for heterogeneity and publication bias was detected. Metformin use in patients with diabetes may be linked to the reduced risk of HCs. FUNDING: No external funding. |
first_indexed | 2024-04-24T08:48:41Z |
format | Article |
id | doaj.art-4f7be2a66c604fe4b1dc5248f102150e |
institution | Directory Open Access Journal |
issn | 0256-4947 0975-4466 |
language | English |
last_indexed | 2024-04-24T08:48:41Z |
publishDate | 2024-03-01 |
publisher | King Faisal Specialist Hospital and Research Centre |
record_format | Article |
series | Annals of Saudi Medicine |
spelling | doaj.art-4f7be2a66c604fe4b1dc5248f102150e2024-04-16T12:52:39ZengKing Faisal Specialist Hospital and Research CentreAnnals of Saudi Medicine0256-49470975-44662024-03-0144212613410.5144/0256-4947.2024.126Metformin and risk of hematological cancers in patients with diabetes: a systematic review and meta-analysisMin Wang0Giti Noghabaei1Tahereh Raeisi2Dandan Li3Hamzeh Alizadeh4Mohammad Alizadeh5From the Department of Endocrinology, Huaihe Hospital of Henan University, Kaifeng, Henan, ChinaFrom the Department of Internal Medicine, Iran University of Medical Sciences, Tehran, IranFrom the Department of Medicine, Hormozgan University of Medical Sciences, Bandar-Abbas, IranFrom the Department of Endocrinology, Huaihe Hospital of Henan University, Kaifeng, Henan, ChinaFrom the Department of Genetics and Breeding, University of Guilan, Rasht, Gilan, IranFrom the Department of Medical Surgical Nursing, Mazandaran University of Medical Sciences, Sari, IranThe effect of metformin use in patients with diabetes against the hematological cancers (HCs) has been contradictory. This meta-analysis, carried out on studies published in databases, aimed to investigate the association of metformin use and the odds of HCs. We systematically searched Scopus and PubMed databases to include related studies considering the relation of metformin use and the risk of HCs as outcome. Eleven studies, comprising a total of 2 318 217 participants, were included. The analysis revealed that metformin use in patients with diabetes was significantly associated with a decreased risk of HCs (OR=0.88; 95%CI: 0.79–0.98), with significant heterogeneity. In the subgroup analysis, this association was found to be significant only for multiple myeloma (OR=0.67; 95% CI: 0.55–0.81). A significant evidence for heterogeneity and publication bias was detected. Metformin use in patients with diabetes may be linked to the reduced risk of HCs. FUNDING: No external funding.http://www.annsaudimed.net/doi/10.5144/0256-4947.2024.126 |
spellingShingle | Min Wang Giti Noghabaei Tahereh Raeisi Dandan Li Hamzeh Alizadeh Mohammad Alizadeh Metformin and risk of hematological cancers in patients with diabetes: a systematic review and meta-analysis Annals of Saudi Medicine |
title | Metformin and risk of hematological cancers in patients with diabetes: a systematic review and meta-analysis |
title_full | Metformin and risk of hematological cancers in patients with diabetes: a systematic review and meta-analysis |
title_fullStr | Metformin and risk of hematological cancers in patients with diabetes: a systematic review and meta-analysis |
title_full_unstemmed | Metformin and risk of hematological cancers in patients with diabetes: a systematic review and meta-analysis |
title_short | Metformin and risk of hematological cancers in patients with diabetes: a systematic review and meta-analysis |
title_sort | metformin and risk of hematological cancers in patients with diabetes a systematic review and meta analysis |
url | http://www.annsaudimed.net/doi/10.5144/0256-4947.2024.126 |
work_keys_str_mv | AT minwang metforminandriskofhematologicalcancersinpatientswithdiabetesasystematicreviewandmetaanalysis AT gitinoghabaei metforminandriskofhematologicalcancersinpatientswithdiabetesasystematicreviewandmetaanalysis AT taherehraeisi metforminandriskofhematologicalcancersinpatientswithdiabetesasystematicreviewandmetaanalysis AT dandanli metforminandriskofhematologicalcancersinpatientswithdiabetesasystematicreviewandmetaanalysis AT hamzehalizadeh metforminandriskofhematologicalcancersinpatientswithdiabetesasystematicreviewandmetaanalysis AT mohammadalizadeh metforminandriskofhematologicalcancersinpatientswithdiabetesasystematicreviewandmetaanalysis |